BLUEJAY DIAGNOSTICS INC (BJDX)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$2.19-4.37%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · BJDX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -88.6% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 29 industry peers
BJDX — capital allocation
Dated 2026-11-04
of Form 8-K, the information regarding the Reverse Stock Split (as defined herein) contained in
Why it matters: FDA clearance or approval is needed before the test can be sold for clinical use in the United States.
Watch forFDA clears or approves the Symphony IL-6 Test for U.S. clinical use.
Also watch forFDA rejects the application, asks for more data, or the company reports that review is delayed.
Why it matters: Cash needs and SYMON-II analysis are key near-term tests. Bluejay has reported a high risk signal and weak RFP status.
Watch forThe November 6 update says cash will last beyond Q2 2027. It gives a date to finish SYMON-II analysis.
Also watch forThe update says cash will run out before Q2 2027, or delays SYMON-II analysis without giving a new date.
Why it matters: The company plans to use SYMON-II to support a 510(k) filing. FDA review is needed before U.S. sales.
Supportive ifBluejay files a 510(k) application for the Symphony IL-6 Test and discloses the filing date.
Worry ifBluejay says the planned 510(k) filing is delayed, or that it will not file using SYMON-II data.
Why it matters: The 777-patient study is meant to test whether IL-6 links to death risk. The results may shape the planned FDA filing.
Watch forFinal SYMON-II results show that IL-6 is linked to 28-day mortality. They report clear test measures.
Also watch forFinal results show no useful link between IL-6 levels and 28-day mortality. Or, they do not report key test measures.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$398 on $10,000 · ±4.0% | How much price usually moves either way. |
| Bad day | $1,137 loss on $10,000 · 11.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,260 loss on $10,000 · 92.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Management has said the company needs more capital. Its Q2 cash was estimated to fund operations through Q2 2027.
Watch forBluejay reports at least $20 million in new capital raised by December 31, 2027.
Also watch forBluejay reports less than $20 million raised by December 31, 2027, or says its cash runs out before then.